Colorectal Cancer Clinical Trial
Official title:
Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may
also stop the growth of tumor cells by blocking blood flow to the tumor.Drugs used in
chemotherapy, such as leucovorin, oxaliplatin, and fluorouracil, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving cetuximab together with combination chemotherapy and bevacizumab before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed. Giving these treatments after surgery may kill any tumor cells that remain after
surgery.
PURPOSE: This randomized phase II trial is studying the side effects and how well giving
cetuximab together with leucovorin, oxaliplatin, and fluorouracil works with or without
bevacizumab in treating patients with resectable liver metastases from colorectal cancer.
OBJECTIVES:
- Compare the safety and activity of neoadjuvant and adjuvant cetuximab, leucovorin
calcium, oxaliplatin, and fluorouracil with vs without bevacizumab in patients with
resectable liver metastases secondary to colorectal cancer.
OUTLINE: This is an open-label, randomized, multicenter study. Patient are stratified
according to participating center and planned liver resection (major [≥ 3 segments] vs minor
[< 3 segments]). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2
hours on day 1 and fluorouracil IV over 46 hours (FOLFOX) beginning on day 1. Patients
also receive cetuximab IV over 1-2 hours on days 1 and 8. Treatment repeats every 14
days for 6 courses in the absence of disease progression or unacceptable toxicity.
Between 3-5 weeks after completion of FOLFOX and cetuximab, patients undergo liver
resection. Beginning between 4-8 weeks after surgery, patients receive another 6 courses of
FOLFOX and cetuximab as in neoadjuvant therapy.
- Arm II: Patients receive FOLFOX and cetuximab as in arm I and bevacizumab IV over 30-90
minutes on day 1. Treatment repeats every 14 days for 6 courses* in the absence of
disease progression or unacceptable toxicity.
NOTE: *Patients do not receive bevacizumab during course 6
Between 3-5 weeks after completion of FOLFOX, cetuximab, and bevacizumab, patients undergo
liver resection. Beginning between 4-8 weeks after surgery, patients receive another 6
courses of FOLFOX, cetuximab, and bevacizumab as in neoadjuvant therapy.
After completion of study treatment, patients are followed every 3 months for 2 years and
then every 6 months for at least 3 years.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |